Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges.
Ebola outbreak
Ebola vaccines
Ebola virus disease (EVD)
challenges
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
26 Jan 2023
26 Jan 2023
Historique:
received:
12
12
2022
revised:
14
01
2023
accepted:
23
01
2023
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
1
3
2023
Statut:
epublish
Résumé
The global outgoing outbreaks of Ebola virus disease (EVD) in different regions of Sudan, Uganda, and Western Africa have brought into focus the inadequacies and restrictions of pre-designed vaccines for use in the battle against EVD, which has affirmed the urgent need for the development of a systematic protocol to produce Ebola vaccines prior to an outbreak. There are several vaccines available being developed by preclinical trials and human-based clinical trials. The group of vaccines includes virus-like particle-based vaccines, DNA-based vaccines, whole virus recombinant vaccines, incompetent replication originated vaccines, and competent replication vaccines. The limitations and challenges faced in the development of Ebola vaccines are the selection of immunogenic, rapid-responsive, cross-protective immunity-based vaccinations with assurances of prolonged protection. Another issue for the manufacturing and distribution of vaccines involves post authorization, licensing, and surveillance to ensure a vaccine's efficacy towards combating the Ebola outbreak. The current review focuses on the development process, the current perspective on the development of an Ebola vaccine, and future challenges for combatting future emerging Ebola infectious disease.
Identifiants
pubmed: 36851146
pii: vaccines11020268
doi: 10.3390/vaccines11020268
pmc: PMC9963029
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
PLoS Pathog. 2013;9(5):e1003389
pubmed: 23737747
J Infect Dis. 2020 Jul 23;222(4):572-582
pubmed: 31603201
JAMA. 2016 Apr 19;315(15):1610-23
pubmed: 27092831
J Infect Dis. 2011 Nov;204 Suppl 3:S1053-9
pubmed: 21987741
N Engl J Med. 2016 Oct 13;375(15):1448-1456
pubmed: 27732819
Trends Microbiol. 2007 Sep;15(9):408-16
pubmed: 17698361
Hum Vaccin Immunother. 2017 Jan 2;13(1):153-168
pubmed: 27764560
Mil Med Res. 2015 Mar 10;2:7
pubmed: 26000173
Curr Top Microbiol Immunol. 2017;411:195-227
pubmed: 28653189
J Virol. 2006 Mar;80(5):2267-79
pubmed: 16474134
Annu Rev Microbiol. 2018 Sep 08;72:423-446
pubmed: 30200851
Curr Infect Dis Rep. 2015 May;17(5):480
pubmed: 25896751
Nature. 2000 Nov 30;408(6812):605-9
pubmed: 11117750
PLoS Negl Trop Dis. 2011 Aug;5(8):e1275
pubmed: 21858240
Vitam Horm. 2021;117:157-187
pubmed: 34420579
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
Lancet Infect Dis. 2020 Apr;20(4):455-466
pubmed: 31952923
J Immunol. 2005 Jul 15;175(2):1184-91
pubmed: 16002721
Ther Adv Vaccines. 2015 Sep;3(5-6):125-38
pubmed: 26668751
J Infect Dis. 2015 Feb 15;211(4):549-57
pubmed: 25225676
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Vaccines (Basel). 2022 Jul 29;10(8):
pubmed: 36016099
J Infect Dis. 2016 Apr 1;213(7):1124-33
pubmed: 26715676
J Infect Dis. 2011 Nov;204 Suppl 3:S1066-74
pubmed: 21987743
J Formos Med Assoc. 2020 May;119(5):982-989
pubmed: 32307322
PLoS Pathog. 2010 May 20;6(5):e1000904
pubmed: 20502688
J Infect Dis. 2015 Oct 1;212 Suppl 2:S91-7
pubmed: 26063223
BMJ Open. 2021 Sep 28;11(9):e046835
pubmed: 34588237
Hum Vaccin Immunother. 2017 Mar 4;13(3):613-620
pubmed: 28152326
Emerg Infect Dis. 2002 May;8(5):503-7
pubmed: 11996686
Virus Genes. 2017 Aug;53(4):501-515
pubmed: 28447193
PLoS Pathog. 2021 Dec 9;17(12):e1010078
pubmed: 34882741
Front Immunol. 2017 Mar 10;8:252
pubmed: 28344580
Sci Transl Med. 2012 Oct 31;4(158):158ra146
pubmed: 23115355
J Virol. 2008 Jun;82(11):5664-8
pubmed: 18385248
Expert Rev Vaccines. 2014 Apr;13(4):521-31
pubmed: 24575870
Trends Biotechnol. 2004 Jul;22(7):346-53
pubmed: 15245907
Mol Pharm. 2015 Aug 3;12(8):2712-31
pubmed: 25363619
N Engl J Med. 2016 Apr 28;374(17):1635-46
pubmed: 25629663
J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7
pubmed: 17940980
Clin Immunol. 2016 Dec;173:44-49
pubmed: 27910805
Vaccine. 2014 Sep 29;32(43):5722-9
pubmed: 25173474
J Virol. 2000 Aug;74(15):6821-31
pubmed: 10888621
Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1129-33
pubmed: 18212124
Lancet. 2018 Sep 1;392(10149):787-790
pubmed: 30104048
Expert Rev Vaccines. 2019 Dec;18(12):1229-1242
pubmed: 31779496
Curr Opin Pharmacol. 2021 Oct;60:46-53
pubmed: 34329960
Sci Rep. 2022 May 11;12(1):7757
pubmed: 35545650
Curr Opin Virol. 2017 Apr;23:88-94
pubmed: 28460340
Science. 2015 Apr 24;348(6233):439-42
pubmed: 25814063
Curr Opin Virol. 2022 Jun;54:101210
pubmed: 35287095
Lancet. 2017 Feb 11;389(10069):621-628
pubmed: 28017399
Hum Vaccin Immunother. 2012 Nov 1;8(11):1703-6
pubmed: 22922764
Expert Rev Vaccines. 2008 Mar;7(2):175-91
pubmed: 18324888
Clin Vaccine Immunol. 2006 Nov;13(11):1267-77
pubmed: 16988008
Hum Vaccin Immunother. 2015;11(8):1991-2004
pubmed: 25996997
Mol Ther. 2013 Jul;21(7):1432-44
pubmed: 23670573
Lancet. 2015 Apr 18;385(9977):1545-54
pubmed: 25540891
Open Forum Infect Dis. 2022 Mar 07;9(4):ofac052
pubmed: 35265726